TN2013000532A1 - Inhibitors of t-cell activation - Google Patents

Inhibitors of t-cell activation

Info

Publication number: TN2013000532A1
Authority: TN; Tunisia
Prior art keywords: inhibitors; cell activation; ligand specific; ctla; provides
Prior art date: 2011-06-30

Application number

TNP2013000532A

Other languages

English (en)

Inventor

Yunxiang Zhu

Jozsef Karman

Ronnie Wei

Canwen Jiang

Seng Cheng

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-30

Filing date

2013-12-26

Publication date

2015-03-30

2013-12-26 Application filed by Genzyme Corp filed Critical Genzyme Corp

2015-03-30 Publication of TN2013000532A1 publication Critical patent/TN2013000532A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Zoology (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Cell Biology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Neurology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)

TNP2013000532A 2011-06-30 2013-12-26 Inhibitors of t-cell activation TN2013000532A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161503282P	2011-06-30	2011-06-30
PCT/US2012/045017 WO2013003761A1 (fr)	2011-06-30	2012-06-29	Inhibiteurs de l'activation des lymphocytes t

Publications (1)

Publication Number	Publication Date
TN2013000532A1 true TN2013000532A1 (en)	2015-03-30

Family

ID=47424568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000532A TN2013000532A1 (en)	2011-06-30	2013-12-26	Inhibitors of t-cell activation

Country Status (35)

Country	Link
US (4)	US9834604B2 (fr)
EP (2)	EP3357511B1 (fr)
JP (4)	JP6157461B2 (fr)
KR (1)	KR20140058532A (fr)
CN (2)	CN103796681B (fr)
AU (3)	AU2012275133B2 (fr)
BR (1)	BR112013033661A2 (fr)
CA (1)	CA2839462A1 (fr)
CL (1)	CL2013003725A1 (fr)
CO (1)	CO6841996A2 (fr)
CR (1)	CR20130661A (fr)
DK (2)	DK2726101T3 (fr)
DO (1)	DOP2013000313A (fr)
ES (2)	ES2694749T3 (fr)
GT (1)	GT201300323A (fr)
HK (1)	HK1258401A1 (fr)
HR (1)	HRP20181786T1 (fr)
HU (1)	HUE040455T2 (fr)
LT (1)	LT2726101T (fr)
MA (1)	MA35280B1 (fr)
MX (1)	MX354922B (fr)
MY (1)	MY180616A (fr)
NI (1)	NI201300140A (fr)
PE (1)	PE20141469A1 (fr)
PH (1)	PH12013502684A1 (fr)
PL (2)	PL3357511T3 (fr)
PT (2)	PT3357511T (fr)
RS (1)	RS57996B1 (fr)
RU (1)	RU2657440C2 (fr)
SG (1)	SG10201604715VA (fr)
SI (1)	SI2726101T1 (fr)
TN (1)	TN2013000532A1 (fr)
UA (1)	UA116191C2 (fr)
WO (1)	WO2013003761A1 (fr)
ZA (1)	ZA201309532B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2647707T (pt)	2010-11-30	2018-11-15	Chugai Pharmaceutical Co Ltd	Agente terapêutico indutor de toxicidade
DK2726101T3 (en) *	2011-06-30	2018-12-03	Genzyme Corp	T-CELL ACTIVATION INHIBITORS
US8956619B2 (en) *	2011-10-25	2015-02-17	University Of Maryland, Baltimore County	Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
SG11201504558TA (en)	2012-12-11	2015-07-30	Einstein Coll Med	Methods for high throughput receptor:ligand identification
GB201311487D0 (en) *	2013-06-27	2013-08-14	Alligator Bioscience Ab	Bispecific molecules
TWI852057B (zh)	2014-03-14	2024-08-11	瑞士商諾華公司	針對lag-3之抗體分子及其用途
ES2900898T3 (es)	2014-04-07	2022-03-18	Chugai Pharmaceutical Co Ltd	Anticuerpos biespecíficos inmunoactivadores
CN106459954A (zh) *	2014-05-13	2017-02-22	中外制药株式会社	用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
TWI693232B (zh)	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN105296433B (zh)	2014-08-01	2018-02-09	中山康方生物医药有限公司	一种ctla4抗体、其药物组合物及其用途
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3229586A4 (fr)	2014-12-10	2018-10-24	Regents of the University of Minnesota	Cellules, tissus et organes génétiquement modifiés pour le traitement d'une maladie
CN104459129A (zh) *	2015-01-05	2015-03-25	复旦大学附属华山医院	一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒
PT3283508T (pt)	2015-04-17	2021-06-21	Alpine Immune Sciences Inc	Proteínas imuno modulatórias com afinidades afináveis
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
KR102761886B1 (ko)	2015-07-30	2025-02-06	마크로제닉스, 인크.	Pd-1-결합 분자 및 그것의 사용 방법
KR20180054713A (ko) *	2015-09-14	2018-05-24	알파인 이뮨 사이언시즈, 인코포레이티드	조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법
PE20181300A1 (es)	2015-11-02	2018-08-09	Five Prime Therapeutics Inc	Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
EP3378488A4 (fr)	2015-11-18	2019-10-30	Chugai Seiyaku Kabushiki Kaisha	Procédé pour renforcer la réponse immunitaire humorale
WO2017086367A1 (fr)	2015-11-18	2017-05-26	中外製薬株式会社	Polythérapie utilisant une molécule de liaison à l'antigène à rôle de redirection des cellules t, ciblant des cellules immunosupressives
MA44082A (fr)	2015-12-14	2018-10-24	Macrogenics Inc	Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
KR101918456B1 (ko) *	2015-12-15	2018-11-16	앱클론(주)	Cd80 및 cd86에 특이적으로 결합하는 항체
MX2018007406A (es)	2015-12-16	2018-08-15	Merck Sharp & Dohme	Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
EP3192805A1 (fr)	2016-01-15	2017-07-19	Humanitas Mirasole S.p.A.	Inhibiteurs de l'activation ou la stimulation des lymphocytes t et leurs utilisations
KR20180132663A (ko) *	2016-03-02	2018-12-12	큐 바이오파마, 인크.	T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
CN109312402A (zh) *	2016-04-11	2019-02-05	得克萨斯州大学系统董事会	用于检测单个t细胞受体亲和力和序列的方法和组合物
KR20230051602A (ko)	2016-04-15	2023-04-18	알파인 이뮨 사이언시즈, 인코포레이티드	Icos 리간드 변이체 면역조절 단백질 및 그의 용도
US11078282B2 (en)	2016-04-15	2021-08-03	Alpine Immune Sciences, Inc.	CD80 variant immunomodulatory proteins and uses thereof
KR20190044029A (ko)	2016-05-18	2019-04-29	알버트 아인슈타인 컬리지 오브 메디슨, 인크.	변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
BR112018073606A2 (pt)	2016-05-18	2019-02-26	Cue Biopharma, Inc.	polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
US11834490B2 (en)	2016-07-28	2023-12-05	Alpine Immune Sciences, Inc.	CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
WO2018035710A1 (fr)	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anticorps anti-ctla4
CN117024560A (zh)	2016-12-22	2023-11-10	库尔生物制药有限公司	T细胞调节性多聚体多肽及其使用方法
EP3565829A4 (fr)	2017-01-09	2021-01-27	Cue Biopharma, Inc.	Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
EP4431109A3 (fr)	2017-03-15	2024-11-27	Cue Biopharma, Inc.	Combinaison de polypeptides de fusion multimères et d'inhibiteur de point de contrôle immunitaire pour le traitement du cancer associé au hpv
WO2018170023A1 (fr)	2017-03-16	2018-09-20	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices à variants pd-l2 et utilisations associées
WO2018170026A2 (fr)	2017-03-16	2018-09-20	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices à variants de cd80 et leurs utilisations
JP2020517913A (ja)	2017-04-28	2020-06-18	ファイブプライムセラピューティクス，インコーポレイテッド	Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
EP4219540A3 (fr)	2017-10-10	2023-12-06	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices à variants ctla-4 et leurs utilisations
WO2019079520A2 (fr)	2017-10-18	2019-04-25	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
CN111741746A (zh) *	2017-11-29	2020-10-02	乌第有限合伙公司	治疗自身免疫性疾病的方法
CN108003238B (zh) *	2017-11-30	2021-02-02	常州费洛斯药业科技有限公司	一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
WO2019139896A1 (fr)	2018-01-09	2019-07-18	Cue Biopharma, Inc.	Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
EP3747456A4 (fr) *	2018-01-31	2021-12-01	Tohoku University	Procédé de régulation de l'expression du cmh spécifique d'un antigène
BR112020023195A2 (pt) *	2018-05-14	2021-09-28	Immunocore Limited	Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune
US12065476B2 (en)	2018-06-15	2024-08-20	Alpine Immune Sciences, Inc.	PD-1 variant immunomodulatory proteins and uses thereof
US20230015408A1 (en) *	2019-11-20	2023-01-19	Gi Cell, Inc.	Medium composition for culturing t cells and method for culturing t cells using same
EP4149534A4 (fr)	2020-05-12	2024-09-04	Cue Biopharma, Inc.	Polypeptides multimères modulateurs de lymphocytes t et leurs méthodes d'utilisation
EP4211149A4 (fr)	2020-09-09	2024-10-09	Cue Biopharma, Inc.	Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation
WO2022117572A2 (fr)	2020-12-02	2022-06-09	Oncurious Nv	Agoniste de ltbr utilisé pour la polythérapie contre le cancer
CN114805591A (zh) *	2022-03-31	2022-07-29	浙江大学	靶向ctla-4及配体cd80或cd86的双特异性抗体、筛选方法、组合物及应用
WO2024036287A1 (fr) *	2022-08-12	2024-02-15	Abata Therapeutics, Inc.	Lymphocytes t régulateurs stables et méthodes de production

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5149782A (en)	1988-08-19	1992-09-22	Tanox Biosystems, Inc.	Molecular conjugates containing cell membrane-blending agents
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE297465T1 (de)	1991-11-25	2005-06-15	Enzon Inc	Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ES2156149T3 (es)	1992-12-04	2001-06-16	Medical Res Council	Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
WO1994026087A2 (fr)	1993-05-14	1994-11-24	Connor Kim C O	Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
US5429746A (en)	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
UA71889C2 (uk)	1996-04-02	2005-01-17	Йєда Рісерч Енд Дівелопмент Ко. Лтд.	Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
WO1998023741A1 (fr)	1996-11-28	1998-06-04	Institut Gustave Roussy	Mutants de la proteine lag-3, leur expression et utilisation
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
DE60237282D1 (de)	2001-06-28	2010-09-23	Domantis Ltd	Doppelspezifischer ligand und dessen verwendung
GB0216648D0 (en)	2002-07-18	2002-08-28	Lonza Biologics Plc	Method of expressing recombinant protein in CHO cells
EP1599502A1 (fr) *	2003-02-27	2005-11-30	TheraVision GmbH	Molecule se liant a cd80 et cd86
EP1452868A2 (fr)	2003-02-27	2004-09-01	Pepscan Systems B.V.	Procédé pour sélectionner un médicament d'intérêt potentiel
JP2006523226A (ja) *	2003-02-28	2006-10-12	ザジョンズホプキンスユニバーシティ	Ｔ細胞調節方法
EP1755626A4 (fr) *	2004-05-17	2008-10-01	Univ Illinois	Utilisation de cellules dendritiques revetues d'anticorps bispecifiques (biab), pulsees par antigenes
WO2006029219A2 (fr) *	2004-09-08	2006-03-16	Ohio State University Research Foundation	Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
ES2347340T3 (es) *	2004-09-13	2010-10-28	Genzyme Corporation	Construcciones multimericas.
PL1844337T3 (pl)	2005-01-24	2013-12-31	Pepscan Systems Bv	Związki wiążące, związki immunogenne i peptydomimetyki
WO2008073160A2 (fr) *	2006-08-17	2008-06-19	The Trustees Of Columbia University In The City Of New York	Procédés de conversion ou d'induction d'une immunité protectrice
JP2010529859A (ja) *	2007-06-15	2010-09-02	ジェンザイム、コーポレーション	ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
EP2240204A1 (fr) *	2008-02-04	2010-10-20	Medarex, Inc.	Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations
JP6074574B2 (ja)	2008-02-05	2017-02-08	バイシクルセラピューティクスリミテッド	方法及び組成物
JP2011512417A (ja) *	2008-02-20	2011-04-21	ジェンザイム・コーポレーション	血管形成の阻害
AR072999A1 (es) *	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
GB0913775D0 (en)	2009-08-06	2009-09-16	Medical Res Council	Multispecific peptides
DK2726101T3 (en) *	2011-06-30	2018-12-03	Genzyme Corp	T-CELL ACTIVATION INHIBITORS

2012
- 2012-06-29 DK DK12804528.3T patent/DK2726101T3/en active
- 2012-06-29 PE PE2013002910A patent/PE20141469A1/es active IP Right Grant
- 2012-06-29 US US14/128,461 patent/US9834604B2/en active Active
- 2012-06-29 ES ES12804528.3T patent/ES2694749T3/es active Active
- 2012-06-29 PL PL18151718T patent/PL3357511T3/pl unknown
- 2012-06-29 PT PT181517186T patent/PT3357511T/pt unknown
- 2012-06-29 LT LTEP12804528.3T patent/LT2726101T/lt unknown
- 2012-06-29 CN CN201280042085.9A patent/CN103796681B/zh active Active
- 2012-06-29 MX MX2013015384A patent/MX354922B/es active IP Right Grant
- 2012-06-29 RS RS20181350A patent/RS57996B1/sr unknown
- 2012-06-29 ES ES18151718T patent/ES2810424T3/es active Active
- 2012-06-29 SI SI201231438T patent/SI2726101T1/sl unknown
- 2012-06-29 KR KR1020147002646A patent/KR20140058532A/ko not_active Ceased
- 2012-06-29 PT PT12804528T patent/PT2726101T/pt unknown
- 2012-06-29 CA CA2839462A patent/CA2839462A1/fr not_active Abandoned
- 2012-06-29 SG SG10201604715VA patent/SG10201604715VA/en unknown
- 2012-06-29 HU HUE12804528A patent/HUE040455T2/hu unknown
- 2012-06-29 WO PCT/US2012/045017 patent/WO2013003761A1/fr active Application Filing
- 2012-06-29 JP JP2014519165A patent/JP6157461B2/ja active Active
- 2012-06-29 UA UAA201400833A patent/UA116191C2/uk unknown
- 2012-06-29 MY MYPI2013004609A patent/MY180616A/en unknown
- 2012-06-29 EP EP18151718.6A patent/EP3357511B1/fr active Active
- 2012-06-29 CN CN201711283703.XA patent/CN107988156B/zh active Active
- 2012-06-29 AU AU2012275133A patent/AU2012275133B2/en not_active Ceased
- 2012-06-29 PH PH1/2013/502684A patent/PH12013502684A1/en unknown
- 2012-06-29 PL PL12804528T patent/PL2726101T3/pl unknown
- 2012-06-29 RU RU2014102956A patent/RU2657440C2/ru not_active IP Right Cessation
- 2012-06-29 DK DK18151718.6T patent/DK3357511T3/da active
- 2012-06-29 BR BR112013033661A patent/BR112013033661A2/pt not_active Application Discontinuation
- 2012-06-29 EP EP12804528.3A patent/EP2726101B1/fr active Active
2013
- 2013-12-13 CR CR20130661A patent/CR20130661A/es unknown
- 2013-12-18 ZA ZA2013/09532A patent/ZA201309532B/en unknown
- 2013-12-19 NI NI201300140A patent/NI201300140A/es unknown
- 2013-12-26 CL CL2013003725A patent/CL2013003725A1/es unknown
- 2013-12-26 DO DO2013000313A patent/DOP2013000313A/es unknown
- 2013-12-26 TN TNP2013000532A patent/TN2013000532A1/fr unknown
- 2013-12-26 GT GT201300323A patent/GT201300323A/es unknown
- 2013-12-27 CO CO13301377A patent/CO6841996A2/es unknown
2014
- 2014-01-22 MA MA36702A patent/MA35280B1/fr unknown
2017
- 2017-03-08 JP JP2017043440A patent/JP6530436B2/ja active Active
- 2017-10-19 US US15/788,433 patent/US11028170B2/en active Active
- 2017-11-15 AU AU2017261541A patent/AU2017261541B2/en not_active Ceased
2018
- 2018-10-30 HR HRP20181786TT patent/HRP20181786T1/hr unknown
2019
- 2019-01-17 HK HK19100808.1A patent/HK1258401A1/zh unknown
- 2019-05-15 JP JP2019091790A patent/JP6826154B2/ja active Active
- 2019-09-09 AU AU2019226276A patent/AU2019226276B2/en not_active Expired - Fee Related
2021
- 2021-01-14 JP JP2021003877A patent/JP2021073216A/ja active Pending
- 2021-05-03 US US17/306,509 patent/US12043665B2/en active Active
2024
- 2024-06-12 US US18/741,190 patent/US20250002578A1/en active Pending

Also Published As

Publication number	Publication date
ES2810424T3 (es)	2021-03-08
PT3357511T (pt)	2020-07-23
EP2726101B1 (fr)	2018-08-08
PH12013502684A1 (en)	2014-02-17
RS57996B1 (sr)	2019-01-31
EP3357511B1 (fr)	2020-05-13
JP2019151656A (ja)	2019-09-12
JP6530436B2 (ja)	2019-06-12
LT2726101T (lt)	2018-11-26
CL2013003725A1 (es)	2014-07-25
JP6826154B2 (ja)	2021-02-03
HRP20181786T1 (hr)	2019-02-08
RU2014102956A (ru)	2015-08-10
AU2019226276A1 (en)	2019-09-26
EP3357511A1 (fr)	2018-08-08
PL2726101T3 (pl)	2019-01-31
DOP2013000313A (es)	2014-07-15
US11028170B2 (en)	2021-06-08
US20140348832A1 (en)	2014-11-27
HUE040455T2 (hu)	2019-03-28
AU2017261541B2 (en)	2019-10-03
DK3357511T3 (da)	2020-08-03
US20250002578A1 (en)	2025-01-02
CN107988156A (zh)	2018-05-04
JP6157461B2 (ja)	2017-07-05
RU2657440C2 (ru)	2018-06-13
CN103796681B (zh)	2018-07-20
CN103796681A (zh)	2014-05-14
EP2726101A4 (fr)	2015-01-28
DK2726101T3 (en)	2018-12-03
US12043665B2 (en)	2024-07-23
JP2014522846A (ja)	2014-09-08
PL3357511T3 (pl)	2020-11-16
CO6841996A2 (es)	2014-01-20
EP2726101A1 (fr)	2014-05-07
NI201300140A (es)	2014-06-26
ZA201309532B (en)	2014-08-27
UA116191C2 (uk)	2018-02-26
MX2013015384A (es)	2014-10-13
CN107988156B (zh)	2022-01-04
AU2019226276B2 (en)	2021-11-11
BR112013033661A2 (pt)	2017-01-24
PE20141469A1 (es)	2014-10-31
MA35280B1 (fr)	2014-07-03
WO2013003761A1 (fr)	2013-01-03
JP2021073216A (ja)	2021-05-13
HK1258401A1 (zh)	2019-11-08
JP2017128585A (ja)	2017-07-27
SG10201604715VA (en)	2016-07-28
KR20140058532A (ko)	2014-05-14
MX354922B (es)	2018-03-26
NZ619473A (en)	2015-06-26
SI2726101T1 (sl)	2018-12-31
AU2017261541A1 (en)	2017-12-07
ES2694749T3 (es)	2018-12-27
PT2726101T (pt)	2018-11-21
CA2839462A1 (fr)	2013-01-03
GT201300323A (es)	2015-02-12
MY180616A (en)	2020-12-03
AU2012275133B2 (en)	2017-08-17
US20180030134A1 (en)	2018-02-01
US20210380686A1 (en)	2021-12-09
US9834604B2 (en)	2017-12-05
AU2012275133A1 (en)	2014-01-16
CR20130661A (es)	2014-04-15

Publication	Publication Date	Title
TN2013000532A1 (en)	2015-03-30	Inhibitors of t-cell activation
MX2012010853A (es)	2013-01-29	Anticuerpos anti-lrp6.
MX342240B (es)	2016-09-21	Anticuerpos anti-fgfr4 y metodos de uso.
MX2014002053A (es)	2014-04-25	Anticuerpos anti -mcsp y metodos de uso.
MX2013015311A (es)	2014-03-31	Polipeptidos de enlace de pcsk9 y metodos de uso.
MX2013008538A (es)	2013-08-12	Amplificador compensado de fijacion de membrana para la secuenciacion de polinucleotido por nanoporo y otras aplicaciones.
EP2867848A4 (fr)	2015-11-25	Systèmes et procédés pour la musique mobile
PH12014500841B1 (en)	2019-11-29	ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
EP2537050A4 (fr)	2015-02-18	Système de sources sismiques larges
MY167655A (en)	2018-09-21	Absorbent article
MX2013001473A (es)	2013-04-29	Anticuerpos contra il-18r1 y usos de los mismos.
PT2721254T (pt)	2018-01-19	Resumo
GB201620333D0 (en)	2017-01-11	Methods and systems for generating cutting paths
IN2014DN07983A (fr)	2015-05-01
MX353951B (es)	2018-02-07	Anticuerpos de anti-teofilina y metodos de uso.
MY168397A (en)	2018-10-31	Method for Illuminating Space
CA143604S (en)	2012-07-16	Equipment availability notifier
MY157836A (en)	2016-07-29	Laminate
GB2506053B (en)	2020-10-28	Methods and systems for generating read-only operating systems
GB2491544A (en)	2012-12-05	Perpetum mobile
PL393982A1 (pl)	2012-08-27	Układ automatycznego zraszania górniczych maszyn urabiających i ładujących
AU334999S (en)	2011-02-04	Accessory (jewellery)
AU335553S (en)	2011-03-22	Earring hook
AU334998S (en)	2011-02-04	Jewellery
AU2011902371A0 (en)	2011-06-30	System and method for seafloor stockpiling